Primed And Boosted Anti-Breast Cancer Tumor Immunity After Autologous Peripheral Blood Stem Cell Transplant (PBSCT): In Vivo Priming With T Cells Armed With Anti-CD3 X anti-Her2/neu Bispecific Antibody (Her2Bi) Pre PBSCT And Boosting After PBSCT With Activated T Cells (ATC)

Abstract

Innovative treatment strategies are needed for women with metastatic breast cancer. In a phase I immunotherapy (IT) trial, infusions of ATC armed with anti-CD3 x anti-Her2/neu bispecific antibody (Her2Bi) induced specific cytotoxicity (SC) in the peripheral blood lymphocytes (PBL) directed at SK-BR-3 breast cancer cells. Armed ATC induced high levels of Th1 cytokines and IL-12 in the serum of patients. After IT, we obtained memory T cells by leukopheresis, expanded the T cells, and re-infused the T cells after PBSCT to test the hypothesis that the transfer of immuneT cells would reconstitute anti-tumor activity after PBSCT.